A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor
Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique